平阳霉素新剂型瘤体内注射治疗婴幼儿血管瘤203例临床分析

doi:10.19438/j.cjoms.2019.03.011

中国口腔颌面外科杂志 ›› 2019, Vol. 17 ›› Issue (3): 247-250.doi: 10.19438/j.cjoms.2019.03.011

平阳霉素新剂型瘤体内注射治疗婴幼儿血管瘤203例临床分析

刘学键¹, 刘志鹏², 武宜雷¹, 邰茂众³

1.山东省临沂经济技术开发区人民医院肿瘤科,山东临沂 276023;
2.山东第一医科大学临床医学系,山东泰安 271000;
3.山东省临沂市肿瘤医院省级血管瘤特色专科,山东临沂 276001

收稿日期:2018-10-10 修回日期:2018-11-28 出版日期:2019-05-20 发布日期:2019-06-21
通讯作者: 邰茂众，E-mail:doudebao@163.com
作者简介:刘学键（1970-）,男,硕士,主任医师,E-mail: lxj168@sina.com

Clinical analysis of 203 cases of infantile hemangioma treated by intralesional injection of a novel pingyangmycin

LIU Xue-jian¹, LIU Zhi-peng², WU Yi-lei¹, TAI Mao-zhong³

1.Department of Oncology, Economic Development Zone People's Hospital. Linyi 276023;
2. Department of Clinical Medicine, Shandong First Medical University. Tai'an 271000;
3.Special Department of Hemangiomas, Linyi Tumor Hospital. Linyi 2760001, Shandong Province, China

Received:2018-10-10 Revised:2018-11-28 Online:2019-05-20 Published:2019-06-21

摘要/Abstract

摘要： 目的: 总结平阳霉素新剂型瘤体内注射治疗婴幼儿血管瘤的临床经验,评价其临床疗效和安全性。方法: 回顾分析2016年4月—2017年4月接受平阳霉素新剂型瘤体内注射治疗的203例婴幼儿血管瘤患儿的临床资料。其中男54例,女149例;年龄2个月~6岁,中位年龄10个月。血管扩张型33例,丘疹型52例,肥厚型59例,深在型30例,混合型29例。初次治疗者147例,前期接受其他治疗者56例,均疗效不佳（其中前期口服普萘洛尔治疗38例,激光治疗18例）。将注射用水+平阳霉素新剂型配成1 mg/mL注射液,从病变周边潜行进针,在病变内注射药物,至瘤体肿胀、表面稍变白为止,勿将药液注射到瘤体深部组织内。每次平阳霉素用量不超过8 mg,病变较大者间隔1个月重复注射1次。采用Achauer等提出的4级分级标准对治疗效果进行评价。采用SPSS 18.0软件包进行统计学分析,各分型等级计数资料疗效比较采用秩和检验,5种分型Ⅳ级疗效率的比较采用χ²检验。结果: 随访1~2年,疗效评定为Ⅰ级0例,Ⅱ级5例,Ⅲ级31例,Ⅳ167例。5种分型的疗效有统计学差异。丘疹型疗效最佳,疗效Ⅳ级占94.2%,依次为血管扩张（93.9%）、肥厚型（91.5%）、深在型（51.7%）和混合型（43.4%）。3例患儿出现注射区轻度色素改变,10例出现低热,2天后自行恢复正常。无高热病例,无瘤体破溃、过敏性休克、肺纤维化病例。结论: 平阳霉素新剂型瘤体内注射治疗婴幼儿血管瘤安全有效,以毛细血管扩张型、丘疹型和肥厚型疗效更佳,建议临床推广应用。

关键词: 婴幼儿血管瘤, 新型平阳霉素制剂, 不良反应

Abstract: PURPOSE: To summarize the clinical experiences of intralesional injection with a novel of pingyangmycin in the treatment of infantile hemangiomas, and to evaluate its clinical efficacy and safety. METHODS: Clinical data of 203 patients with infantile hemangiomas treated with a novel pingyangmycin injection from April 2016 to April 2017 were retrospectively analyzed. There were 54 males and 149 females. Median age was 10 months ranging 2 months to 6 years old. All 203 cases were classified into 5 types according to the classification methods reported by Liu Xue-jian et al. There were 33 cases of telangiectasis type, 52 of papule type, 59 of plump type, 37 of deep type and 22 of mixed type. There were 56 patients having received other treatments in the early stage, all of them responded poorly (including 38 patients receiving oral propranolol and 18 patients with laser therapy). Pingyangmycin injections were performed at a concentration of 1 mg/mL, and the injections did not stop until the tumors had swelling with slightly pale surface. The dose of pingyangmycin should not exceed 8 mg each time, and patients with large lesions were repeatedly injected at an interal of 1 month. The efficacy was evaluated on a 4-level scale proposed by Achauer et al. SPSS 18.0 software package was used for statistical analysis. RESULTS: After follow-up for 1 to 2 years, there were 167 grade Ⅳ cases, 31 grade Ⅲ cases, 5 grade Ⅱcases and 0 gradeⅠ case. There were significant differences in the efficacy among 5 different types. Papule type showed the best curative effect with a Ⅳ efficacy rate of 94.2%, followed by 93.9% in telangiectasis type, 91.5% in plump type, 51.7% in deep type and 43.4% in mixed type. Three children had mild pigmentation changes in the injection area. Fever occurred in 10 patients, but returned to normal 2 days later. There was no case of high fever, necrosis, allergic shock and pulmonary fibrosis. CONCLUSIONS: Injection of a novel pingyangmycin is recommended in the treatment of infantile hemangioma for its safety and effectiveness, especially for the treatment of lesions of papule, telangiectasis, and plump type.

Key words: Infantile hemangioma, Pingyangmycin, Adverse effects

中图分类号:

R739.8

刘学键, 刘志鹏, 武宜雷, 邰茂众. 平阳霉素新剂型瘤体内注射治疗婴幼儿血管瘤203例临床分析[J]. 中国口腔颌面外科杂志, 2019, 17(3): 247-250.

LIU Xue-jian, LIU Zhi-peng, WU Yi-lei, TAI Mao-zhong. Clinical analysis of 203 cases of infantile hemangioma treated by intralesional injection of a novel pingyangmycin[J]. China J Oral Maxillofac Surg, 2019, 17(3): 247-250.

参考文献

[1] Lang F, Press UP.Infantile hemangioma of the eyelid [J]. Ophthalmologe, 2017, 114(12): 1171-1180.
[2] Sagi L, Zvulunov A, Lapidoth M, et al.Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases[J]. Dermatology, 2014, 228(2): 136-144.
[3] Mirbehbahani N, Rashidbaghan A.Treatment process for capillary hemangioma[J]. Iran J Ped Hematol Oncol, 2014, 4(3): 127-130.
[4] 郑家伟, 马坤宁, 张凌. 婴幼儿血管瘤药物治疗概述[J]. 中国口腔颌面外科杂志, 2014, 12(1): 1-5.
[5] 刘学键, 邰茂众, 秦中平, 等. 口服普萘洛尔治疗婴幼儿血管瘤的临床效果分析[J]. 中华医学杂志, 2014, 94(24): 1878-1881.
[6] Waner M, Suen JY.Management of congenital vascular lesions of the head and neck[J]. Oncology (Williston Park), 1995, 9(10): 989-994.
[7] Achauer BM, Chang CJ, Vander Kam VM.Management of hemangioma of infancy: review of 245 patients[J]. Plast Reconstr Surg, 1997, 99(5): 1301-1308.
[8] Grzesik P, Wu JK.Current perspectives on the optimal management of infantile hemangioma[J]. Pediatric Health Med Ther, 2017, 8: 107-116.
[9] Rotter A, de Oliveira ZNP. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol[J]. J Dtsch Dermatol Ges, 2017, 15(12): 1185-1190.
[10] Chinnadurai S, Sathe NA, Surawicz T, et al.Laser treatment of infantile hemangioma: A systematic review[J]. Lasers Surg Med, 2016, 48(3): 221-233.
[11] Menapace D, Mitkov M, Towbin R, et al.The changing face of complicated infantile hemangioma treatment[J]. Pediatr Radiol, 2016, 46(11): 1494-506.
[12] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008, 358(10): 2649-2651.
[13] 秦中平, 刘学键, 李克雷, 等. 小剂量普萘洛尔口服治疗婴儿血管瘤的近期疗效与安全性评价[J]. 中华医学杂志, 2009, 89(44): 3130-3130.
[14] Goss JA, Konczyk DJ, Alomari MH, et al.Propranolol treatment of vascular anomalies other than infantile hemangioma[J]. J Craniofac Surg, 2017, 28(8): 2001-2003.
[15] 邰茂众, 刘学键, 秦中平, 等. 婴幼儿血管瘤口服普萘洛尔治疗后的进一步处理[J]. 上海口腔医学, 2015, 24(6): 716-720.
[16] 刘学键, 秦中平, 李克雷.平阳霉素治疗口腔领面部血管瘤的远期疗效及适应证探讨[J].上海口腔医学, 2001,10(4): 295-298.

平阳霉素新剂型瘤体内注射治疗婴幼儿血管瘤203例临床分析

Clinical analysis of 203 cases of infantile hemangioma treated by intralesional injection of a novel pingyangmycin

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李晓, 范新东, 郑家伟. 脉管异常的ISSVA分类概要及分子生物学研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(3): 286-290.
[2]	郑家伟, 王绪凯, 秦中平, 范新东, 李凯, 杨耀武, 霍然, 刘少华, 赵吉宏, 汪小勇, 周德凯, 刘学键. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识（2022版）[J]. 中国口腔颌面外科杂志, 2022, 20(4): 313-319.
[3]	郑家伟, 赵泽亮, 陈启铭. 婴幼儿血管瘤循证治疗现状[J]. 中国口腔颌面外科杂志, 2022, 20(1): 7-14.
[4]	王杞章, 郑家伟. 口服普萘洛尔治疗婴幼儿增殖期血管瘤:英国儿科皮肤病学会共识及临床指南[J]. 中国口腔颌面外科杂志, 2020, 18(6): 548-552.
[5]	顾达, 霍然, 徐广琪, 毕见海, 李尚滨. 局部外用β受体阻滞剂治疗婴幼儿血管瘤的临床应用研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(4): 375-380.
[6]	李红, 周昱川, 龚忠诚, 孙杨, 凌彬. 口服普萘洛尔联合外用盐酸倍他洛尔治疗8例眶周高风险婴幼儿血管瘤的疗效和安全性评价[J]. 中国口腔颌面外科杂志, 2020, 18(3): 264-268.
[7]	宋会新, 林春男, 王田友, 付兆臣. 普萘洛尔治疗婴幼儿血管瘤的作用机制研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(2): 182-185.
[8]	张凯驰, 徐大朋, 程沫沙, 王绪凯. 马来酸噻吗洛尔和普萘洛尔治疗婴幼儿表浅型血管瘤的疗效分析[J]. 中国口腔颌面外科杂志, 2017, 15(6): 529-533.
[9]	周昱川，凌彬，龚忠诚，许颖捷，陈青立. 外涂盐酸倍他洛尔滴眼液治疗7例表浅型婴幼儿血管瘤疗效观察[J]. 中国口腔颌面外科杂志, 2017, 15(5): 438-441.
[10]	程沫沙，张凯驰，王绪凯. 普萘洛尔治疗溃疡性婴幼儿血管瘤18例临床分析[J]. 中国口腔颌面外科杂志, 2017, 15(3): 264-267.
[11]	王菲楠, 范新东. 放射性核素治疗婴幼儿血管瘤的现状[J]. 中国口腔颌面外科杂志, 2016, 14(5): 471-474.
[12]	彭昊，周国瑜，赵建鑫，沈玲悦，马川. 组织块法建立婴幼儿血管瘤动物模型的实验研究[J]. 中国口腔颌面外科杂志, 2015, 13(6): 486-490.
[13]	王亚飞, 周权, 王忠强. 小剂量盐酸普萘洛尔口服治疗不同月龄婴幼儿血管瘤临床疗效观察[J]. 中国口腔颌面外科杂志, 2015, 13(1): 38-41.
[14]	王佳, 石静, 王绪凯. 0.5%马来酸噻吗洛尔溶液联合普萘洛尔治疗婴幼儿血管瘤的不良反应观察[J]. 中国口腔颌面外科杂志, 2014, 12(6): 539-542.
[15]	郑家伟, 马坤宁, 张凌. 婴幼儿血管瘤药物治疗概述[J]. 中国口腔颌面外科杂志, 2014, 12(1): 1-6.